Rallybio Corp
No SEC Form 4 filings for $RLYB in the last 30 days.
See all $RLYB insider activity →Rallybio reported no revenue and a net loss of $2.73M in 2026, compared to $212K revenue and $16.02M net income in the prior year. The company agreed to merge with Avenzo, with investors providing $215M pre-merger. Rallybio also announced progress in its Phase 1 study of RLYB116.
Rallybio announced an estimated $82.7M special cash distribution, around $13.56 per share, tied to its proposed merger with Avenzo Therapeutics. The final amount may vary and will be paid on November 13, 2026, pending shareholder approval. The record date is expected to be November 5, with the ex-dividend date set for November 6.
Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning RLYB (Rallybio Corp). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent RLYB coverage spans corporate actions, mergers & acquisitions and earnings.
The loss and lack of revenue suggest short‑term pressure, while the merger funding may provide upside if completed.
The cash payout will reduce the company's cash balance and may pressure the share price ahead of the distribution date.
The cash distribution adds immediate value to shareholders, while the merger creates a larger combined biotech entity.
Change in CFO employment status may affect perception of financial leadership stability.
The compensation change may affect investor perception of management stability and merger execution risk.
AlphAI scores every news story that mentions RLYB with an AI model for sentiment and relevance, and aggregates insider trades from Rallybio Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Rallybio reported no revenue and a net loss of $2.73M in 2026, compared to $212K revenue and $16.02M net income in the prior year. The company agreed to merge with Avenzo, with investors providing $215M pre-merger. Rallybio also announced progress in its Phase 1 study of RLYB116.
1 min readRallybio announced an estimated $82.7M special cash distribution, around $13.56 per share, tied to its proposed merger with Avenzo Therapeutics. The final amount may vary and will be paid on November 13, 2026, pending shareholder approval. The record date is expected to be November 5, with the ex-dividend date set for November 6.
1 min readRallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av
2 min readRallybio's CFO Jonathan Lieber will transition to a part-time role while retaining his duties and authority, effective September 15, 2026. He will receive a base salary of $420,000 but is ineligible for annual bonuses during this period. The company did not disclose reasons or replacement plans.
1 min readRallybio Corp (RLYB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, Rallybio Corporation (Rallybio) announced that Jonathan Lieber, Rallybio’s Chief Financial Officer,
1 min readRallyBio, which abandoned a reverse merger with Candid Therapeutics after the plan dissolved, announced a new reverse merger with Avenzo Therapeutics, according to the deal announced Monday. The combined company will trade on Nasdaq as AVZO, raise $215 million, and is expected to close by year-end. RallyBio has faced layoffs and disappointing results since going public in 2021.
4 min readTurn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.
7 min readRallybio receives $7.5 million upfront equity and is eligible for $17.5 million in future milestone payments. The cash runway is now extended into mid-2027 following the asset sale. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday ...
2 min read
